Rare and Orphan Disease Focused
Experienced Management Team
Targeting US/EU Approvals in 2024, 2025 and 2026
Sales infrastructure planned for US and EU markets
Strong KOL support
Founded in 2018, Quoin (QNRX) is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, Scleroderma and others. The company plans to establish a sales infrastructure to commercialize its products in both US and Europe and has entered into strategic licensing partnerships for all other territories.
We are dedicated to finding unique solutions for rare and orphan indications and will continue to expand our pipeline of products to address the unmet needs of underserved patient populations.
Quoin’s executive management and board members are highly experienced business leaders with a track record of successful development and commercialization of therapeutic products for previously unmet medical needs.